![PDF) Toxicological and anatomical study of vegetative organs of Anthurium maricense Nadruz and Mayo (Araceae) PDF) Toxicological and anatomical study of vegetative organs of Anthurium maricense Nadruz and Mayo (Araceae)](https://i1.rgstatic.net/publication/335667977_Toxicological_and_anatomical_study_of_vegetative_organs_of_Anthurium_maricense_Nadruz_and_Mayo_Araceae/links/5d730088299bf1cb808dde8a/largepreview.png)
PDF) Toxicological and anatomical study of vegetative organs of Anthurium maricense Nadruz and Mayo (Araceae)
![Membranes | Free Full-Text | Artificial Intelligence, Machine Learning and Deep Learning in Ion Channel Bioinformatics | HTML Membranes | Free Full-Text | Artificial Intelligence, Machine Learning and Deep Learning in Ion Channel Bioinformatics | HTML](https://www.mdpi.com/membranes/membranes-11-00672/article_deploy/html/images/membranes-11-00672-g003-550.jpg)
Membranes | Free Full-Text | Artificial Intelligence, Machine Learning and Deep Learning in Ion Channel Bioinformatics | HTML
![What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes? - Hematology/Oncology Clinics What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes? - Hematology/Oncology Clinics](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/86c81cdb-ed92-4940-badb-ab7a1605e73e/gr2_lrg.jpg)
What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes? - Hematology/Oncology Clinics
![What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes? - Hematology/Oncology Clinics What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes? - Hematology/Oncology Clinics](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/05fde154-6a63-403d-a3a1-e3428904dc8e/gr1_lrg.jpg)
What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes? - Hematology/Oncology Clinics
![European Crohn´s and Colitis Organisation - ECCO - OP37 Rapidity of symptom improvements during filgotinib induction therapy in patients with Ulcerative Colitis: Post hoc analysis of the phase 2b/3 SELECTION study European Crohn´s and Colitis Organisation - ECCO - OP37 Rapidity of symptom improvements during filgotinib induction therapy in patients with Ulcerative Colitis: Post hoc analysis of the phase 2b/3 SELECTION study](https://cm.ecco-ibd.eu/cmAbstractSubmission/Content/cmabstsms/EC21/abstracts/0000000270/0000012950/Images/Figure3.jpg)